Genzyme Surgical Products
This article was originally published in The Gray Sheet
Executive Summary
Spin-off of the surgical products business of Genzyme General begins trading June 28 on the Nasdaq national market under the ticker symbol GZSP (1"The Gray Sheet" May 31, p. 20)
You may also be interested in...
Genzyme General
Spin-off of surgical products business Genzyme Surgical Products will be effective with the commencement of public trading on the Nasdaq exchange on June 28 under the ticker symbol GZSP. A tax-free dividend of about 0.17967 shares of Genzyme Surgical stock will be distributed for each share of Genzyme General held by shareholders of record on June 14. Upon formation, Genzyme Surgical, which will have about 14.8 mil. shares outstanding after the distribution, will be funded with $150 mil. in cash from Genzyme General. The spin-off will allow Genzyme General to focus more closely on therapeutics and stimulate investment for the development of surgical products ("The Gray Sheet" May 24, p. 21)
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.